참고문헌
- King, H., Aubert, R. E. and Herman, W. H. (1998) Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21, 1414-1431 https://doi.org/10.2337/diacare.21.9.1414
- Stratton, I. M., Adler, A. I., Neil, H. A., Matthews, D. R., Manley, S. E., Cull, C. A., Hadden, D., Turner, R. C. and Holman, R. R. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321, 405-412 https://doi.org/10.1136/bmj.321.7258.405
- Lebovitz, H. E. (2001) Effect of the postprandial state on nontraditional risk factors. Amer. J. Cardio. 88, 20-25
-
Saito, N., Sakai, H., Sekihara, H. and Yajima, Y. (1998) Effect of an
$\alpha -glucosidase$ inhibitor (voglibose), in combination with sulphonilureas, on glycaemic control in type 2 diabetes patients. J. Int. Med. Res. 26, 219-232 -
Puls, W. and Keup, U. (1973) Influence of an
$\alpha -amylase $ inhibitor (Bay d7791) on blood glucose, serum insulin and NEFF in starch loading tests in rats, dogs and man. Diabetologia 9, 97-101 https://doi.org/10.1007/BF01230687 -
Toeller, M. (1994)
${alpha}$ -Glucosidase inhibitors in diabetes: efficacy in NIDDM subjects. Eur. J. Clin. Invest. 24, 31-35 https://doi.org/10.1111/j.1365-2362.1994.tb02253.x -
Rhinehart, B. L., Robinson, K. M., Liu, P. S., Payne, A. J., Wheatley, M. E. and Wanger, S. R. (1987) Inhibition of intestinal disaccharidase and suppression of blood glucose by a new
${\alpha}-glucohydrolase$ inhibitor-MDL 25, 637. J. Pham. Exp. Ther. 241, 915-920 - Lebovitz, H. E. (1998) Postprandial hyperglycemic state: importance and consequences. Diabetes Res. Clin. Pr. 40, 27-37 https://doi.org/10.1016/S0168-8227(98)00039-4
-
Kim, Y. M., Wang M. H. and Rhee H. I. (2004) A novel
${\alpha}-glucosidase$ inhibitor from pine bark. Carbohydrate Res. 339, 715-717 https://doi.org/10.1016/j.carres.2003.11.005 - Hanozet, G., Pircher, H. P., Vanni, P., Oesch, B. and Semenza, G. (1981) An example of enzyme hysteresis. J. Biol. Chem. 256, 3703-3711
- Samulitis, B. K., Goda, T., Lee, S. M. and Koldovsky, O. (1987) Inhibitory mechanism of Acarbose and 1- deoxynojirimycin derivatives on carbohydrates in rat small intestine. Drugs Exp. Clin. Res. 13, 517-524
- Vichayanrat, A., Ploybutr, S., Tunlakit, M. and Watanakejorn, P. (2002) Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Res. Clin. Pr. 55, 99-103 https://doi.org/10.1016/S0168-8227(01)00286-8
- Yasuda, K., Shimowada, K., Uno, M., Odaka, H., Adachi, T., Shihara, N., Suzuki, N., Tamon, A., Nagashima, K., Hosokawa, M., Tsuda, K. and Seino, Y. (2003) Long-term therapeutic effects of voglibose, a potent intestinal alpha-glucosidase inhibitor, in spontaneous diabetic GK rats. Diabetes Res. Clin. Pr. 59, 113-122 https://doi.org/10.1016/S0168-8227(02)00241-3
-
William-Olsson, T. (1985) Carbohydrate digestion and
${\alpha}-glucosidase$ inhibitors. Acta Med. Scand. 706, 5-39 - Campbell, L. K., Baker, D. E. and Campbell, R. K. (2000) Miglitol: assessment of its role in the treatment of patients with diabetes mellitus. Ann. Pharmacother. 34, 1291-1301 https://doi.org/10.1345/aph.19269
- Wood, I. S., Hunter, L. and Trayhurn, P. (2003) Expression of Class III facilitative glucose transporter genes (GLUT-10 and GLUT-12) in mouse and human adipose tissues. Biochem. Biophys. Res. Commun. 308, 43-49 https://doi.org/10.1016/S0006-291X(03)01322-6
- Defronzo, R. A., Bonadonna, R. C. and Ferrannini, E. (1992) Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15, 318-368 https://doi.org/10.2337/diacare.15.3.318
- Defronzo, R. A. and Ferrannini, E. (1991) A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disesse. Diabetes Care 14, 173-194 https://doi.org/10.2337/diacare.14.3.173
- Rea, S. and James, D. E. (1997) Perspectives in diabetes: Moving GLUT4; The biogenesis and trafficking of GLUT4 storage vesicles. Diabetes 46, 1667-1677 https://doi.org/10.2337/diabetes.46.11.1667